Evidence map›Paper›PMID 41990751›Full record

ArticleCell2026

Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition.

José Reyes, Isabella Del Priore, Andrea C Chaikovsky, Nikhita Pasnuri, Ahmed M Elhossiny, Jin Park, Philipp Weiler, Tobias Krause, Andrew Moorman, Catherine Snopkowski and 15 more

Abstract read
In one paragraph

Article in Cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

José ReyesCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Isabella Del PrioreCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrea C ChaikovskyCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nikhita PasnuriComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Single-Cell Analytics Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ahmed M ElhossinyDepartment of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Jin ParkComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Philipp WeilerComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tobias KrauseSingle-Cell Analytics Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew MoormanSingle-Cell Analytics Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Catherine SnopkowskiSingle-Cell Analytics Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Meril TakizawaSingle-Cell Analytics Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Biological and Biomedical Sciences, Harvard Medical School, Boston, MA, USA.
Cassandra BurdziakComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nalin RatnayekeCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ignas MasilionisSingle-Cell Analytics Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yu-Jui HoCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ronan ChalignéSingle-Cell Analytics Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul B RomesserDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aveline FilliolCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tal NawyComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
John P MorrisCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pharmacology, The University of North Carolina at Chapel Hill Medical School, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Zhen ZhaoCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Cold Spring Harbor Laboratory, New York, NY, USA; Department of Pathology and Laboratory Medicine, Northwell Health System, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.
Marina Pasca Di MaglianoRogel Cancer Center, University of Michigan, Ann Arbor, MI, USA; Department of Surgery, University of Michigan, Ann Arbor, MI, USA.
Direna Alonso-CurbeloCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Dana Pe'erComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA. Electronic address: peerster@gmail.com.
Scott W LoweCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA. Electronic address: lowes@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Michael Jason de la Cruz · 1985 to 2026
$347.4M
Mutant p53 in Tumorigenesis, Invasion, and MetastasisP01CA291694 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI James J Manfredi · 2025 to 2026
$7.9M
Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic TumorigenesisR01CA283378 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCOTT W. LOWE, Dana Pe'er · 2023 to 2026
$2.9M
Leveraging Radiation-Induced Senescence and PTPN2 Inhibition to Enhance Immune-Mediated Tumor Control in Rectal CancerR37CA304010 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Paul Bernard Romesser · 2025 to 2026
$1.5M
Investigating the contribution of cellular senescence to the efficacy of radiation therapy.K08CA255574 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROMESSER, PAUL BERNARD · 2021 to 2025
$1.2M
Investigating the Role of Cell Plasticity in Malignant TransformationK00CA245471 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHAIKOVSKY, ANDREA CHRISTINE · 2022 to 2025
$389k
NCI NIH HHS K00 CA245471NCI NIH HHS K08 CA255574NCI NIH HHS P01 CA291694NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA283378NCI NIH HHS R37 CA304010
6 · The paper itself

Abstract

The benign-to-malignant transition is a defining step in cancer progression. To investigate when and how malignancy initiation occurs and tissue reorganization proceeds, we combine single-cell and spatial transcriptomic profiling in mouse models of pancreatic ductal adenocarcinoma (PDAC) that capture spontaneous p53 loss. Among Kras-mutant cells, we find that oncogenic and tumor-suppressive programs, including those controlled by p53, CDKN2A, and SMAD4, are co-activated in a discrete progenitor-like population, engaging senescence-like responses. Using a framework we developed for spatial analysis, we show that a niche centered on these cells undergoes stepwise remodeling during tumor progression, mirroring invasive PDAC. Transient KRAS inhibition depletes progenitor-like cells and dismantles their niche, delaying malignancy initiation. Conversely, p53 suppression enables progenitor cell expansion, epithelial-mesenchymal reprogramming, and immune-privileged niche formation. These findings position the progenitor-like state at the convergence of cancer-driving mutations, plasticity, and tissue remodeling, revealing a critical window for intercepting malignancy.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsStem Cell NicheAnimalsCyclin-Dependent Kinase Inhibitor p16Epithelial-Mesenchymal TransitionHumansMiceNeoplastic Stem CellsProto-Oncogene Proteins p21(ras)Smad4 ProteinTumor Suppressor Protein p53Cyclin-Dependent Kinase Inhibitor p16Hras protein, mouseProto-Oncogene Proteins p21(ras)Smad4 ProteinSmad4 protein, mouseTrp53 protein, mouseTumor Suppressor Protein p53benign-to-malignant transitionKRAS inhibitorsniche dynamicsp53pancreatic cancersingle-cell biologyspatial transcriptomicstumor initiationtumor suppression

Identifiers

PMID41990751
PMCPMC13173668

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.